AIM: To evaluate the outcome of prostate cancer patients with initial PSA value >40 ng/ml. BACKGROUND: The outcome of prostate cancer patients with very high initial PSA value is not known and patients are frequently treated with palliative intent. We analyzed the outcome of radical combined hormonal treatment and radiotherapy in prostate cancer patients with initial PSA value >40 ng/ml. METHODS: Between January 2003 and December 2007 we treated, with curative intent, 56 patients with non-metastatic prostate cancer and initial PSA value >40 ng/ml. The treatment consisted of two months of neoadjuvant hormonal treatment (LHRH analog), radical radiotherapy (68-78 Gy, conformal technique) and an optional two-year adjuvant hormonal treatment. RESULTS: The median time of follow up was 61 months. 5-Year overall survival was 90%. 5-Year biochemical disease free survival was 62%. T stage, Gleason score, PSA value, and radiotherapy dose did not significantly influence the outcome. Late genitourinal and gastrointestinal toxicity was acceptable. CONCLUSION: Radical treatment in combination with hormonal treatment and radiotherapy can be recommended for this subgroup of prostate cancer patients with good performance status and life expectancy.

Institute of Radiation Oncology Faculty Hospital Na Bulovce and 1 Faculty of Medicine Charles University Budínova 2 Prague 8 18000 Czech Republic

Oncological Clinic Faculty Hospital Ostrava 17 listopadu 1790 Ostrava Poruba 708 52 Czech Republic

Zobrazit více v PubMed

Caire A.A., Sun L., Lack B.D. Predicting non-organ-confined prostate cancer in men diagnosed after 2000. Prostate Cancer Prostatic Dis. 2010;13:248–251. PubMed

Partin A.W., Kattan M.W., Subong E.N. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445–1451. PubMed

Gallina A., Jeldres C., Chun F.K. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol. 2007;52:1374–1380. PubMed

Anim J.T., Kehinde E.O., Prasad A. Relationship between serum prostate specific antigen and the pattern of inflammation in both benign and malignant prostatic disease in Middle Eastern men International. Urol Nephrol. 2006;38:27–32. PubMed

Schirrmeister H., Guhlmann A., Elsner K. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40:1623–1629. PubMed

Even-Sapir E., Metser U., Mishani E. The detection of bone metastases in patients with high risk prostate cancer: 99mTc MDP planar bone scintigraphy, single and multi field of view SPECT, 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–297. PubMed

Eschmann S.M., Pfannenberg A.C., Rieger A. Comparison of 11C-choline PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin. 2007;46:161–168. PubMed

Scattoni V., Picchio M., Suardi N. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Radiol. 2007;52:423–429. PubMed

Widmark A., Klepp O., Solberg A. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–308. PubMed

Bolla M., Collette L., Blank L. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–106. PubMed

Bolla M., van Tienhoven G., de Reijke T.M. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT: results of the randomized EORTC Phase III trial 22,961. J Clin Oncol. 2007;25:5014.

Gallina A., Jeldres C., Chun F. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol. 2007;52:1374–1380. PubMed

Gleave M.E., Coupland D., Drachenberg D. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology. 1996;47:708–712. PubMed

Jung K., Lein M., Stephan C. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer. 2004;111:783–791. PubMed

Kamiya N., Suzuki H., Yano M. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Urology. 2010;75:1446–1451. PubMed

Kataoka A., Yuasa T., Kageyama S. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen. Clin Oncol. 2006;18(August (6)):480–484. PubMed

Hovels A.M., Heesakkers R.A., Adang E.M. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387–395. PubMed

Testa C., Schiavina R., Lodi R. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET-CT. Radiology. 2007;244:797–806. PubMed

Yamaguchi T., Lee J., Uemura H. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32:742–748. PubMed

Bauman G., Belhocine T., Kovacs M., Ward A., Beheshti M., Rachinsky I. (18)F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2011 August 16 [Epub ahead of print] PubMed

Beheshti M., Imamovic L., Broinger G. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925–933. PubMed

Beheshti M., Vali R., Waldenberger P. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2009;11:446–454. PubMed

Roach M., 3rd, Bae K., Speight J. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of rtog 8610. J Clin Oncol. 2008;26:585–591. PubMed

D’Amico A.V., Chen M.H., Renshaw A.A., Loffredo M., Kantoff P.W. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289–295. PubMed

Denham J.W., Steigler A., Lamb D.S. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841–850. PubMed

Alexander A., Crook J., Jones S. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. Int J Radiat Oncol Biol Phys. 2010;76:23–30. PubMed

Roach M., III, DeSilvio M., Valicenti R. Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006;3:647–653. PubMed

Lawton C.A., DeSilvio M., Roach M., III An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69:646–655. PubMed PMC

Dirix P., Haustermans K., Junius S., Withers R., Oyen R., Van Poppel H. The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiother Oncol. 2006;79:1–14. PubMed

Cheung R., Tucker S., Lee A. Dose–response characteristics of low- and intermediate risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:993–1002. PubMed

Pollack A., Zagars G., Starkschall G. Prostate Cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105. PubMed

Sharma N.K., Li T., Chen D.Y., Pollack A., Horwitz E.M., Buyyounouski M.K. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 November 2 [Epub ahead of print] PubMed

Dolezel M., Odrazka K., Vaculikova M. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol. 2010;186(April (4)):197–202. PubMed

Ceylan C., Kucuk N., Bas Ayata H., Guden M., Engin K. Dosimetric and physical comparison of IMRT and CyberKnife plans in the treatment of localized prostate cancer. Rep Pract Oncol Radiother. 2010;15(6):181–189. PubMed PMC

Ashman J.B., Zelefsky M.J., Hunt M.S., Leibel S.A., Fuks Z. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:765–771. PubMed

De Meerleer G., Fonteyne V.H., Vakaet L. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical kontrol. Radiother Oncol. 2007;82:160–166. PubMed

Bolla M., Gonzalez D., Warde P. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300. PubMed

Bajon T., Piotrowski T., Antczak A. Comparison of dose volume histograms for supine and prone position in patients irradiated for prostate cancer—a preliminary study. Rep Pract Oncol Radiother. 2011;16:65–70. PubMed PMC

Tyrrella C.H., Payneb H., Seec W.A. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme Group. Radiother Oncol. 2005;76:4–10. PubMed

Keating N.L., O’Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456. PubMed

Saigal C.S., Gore J.L., Krupski T.L., Hanley J., Schonlau M., Litwin M.S. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–1500. PubMed

Alibhai S.M., Duong-Hua M., Sutradhar R. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27:3452–3458. PubMed PMC

Alexander A.S., Mydin A., Jones S.O. Extreme-risk prostate adenocarcinoma with prostate-specific antigen (PSA) > 40 ng/ml: prognostic significance of the preradiation PSA nadir. Int J Radiat Oncol Biol Phys. 2011 January 27 [Epub ahead of print] PubMed